Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD)
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2018
At a glance
- Drugs Abicipar pegol (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms MAPLE
- Sponsors Allergan
- 29 Nov 2018 According to a Molecular Partners AG media release, results are anticipated in H1 2019.
- 01 Nov 2018 According to a Molecular Partners AG media release, MAPLE trial run by partner Allergan fully recruited in Q3 2018, testing further optimized formulation of abicipar. Results expected in H1 2019 and Allergan plans to file abicipar with FDA in H1 2019 pending pre-BLA meeting.
- 01 Jun 2018 Status changed from not yet recruiting to recruiting.